CN118715010A - 包含二苯基二唑衍生物的药物组合物及其使用方法 - Google Patents

包含二苯基二唑衍生物的药物组合物及其使用方法 Download PDF

Info

Publication number
CN118715010A
CN118715010A CN202380024479.XA CN202380024479A CN118715010A CN 118715010 A CN118715010 A CN 118715010A CN 202380024479 A CN202380024479 A CN 202380024479A CN 118715010 A CN118715010 A CN 118715010A
Authority
CN
China
Prior art keywords
pharmaceutical composition
fatty acid
anle138b
polyethylene glycol
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380024479.XA
Other languages
English (en)
Chinese (zh)
Inventor
阿米尼·吉斯
约翰内斯·莱文
埃马努埃拉·德尔韦斯科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Modago Co ltd
Original Assignee
Modago Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modago Co ltd filed Critical Modago Co ltd
Publication of CN118715010A publication Critical patent/CN118715010A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202380024479.XA 2022-03-01 2023-03-01 包含二苯基二唑衍生物的药物组合物及其使用方法 Pending CN118715010A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22159408 2022-03-01
EP22159408.8 2022-03-01
PCT/EP2023/055160 WO2023166045A1 (en) 2022-03-01 2023-03-01 Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use

Publications (1)

Publication Number Publication Date
CN118715010A true CN118715010A (zh) 2024-09-27

Family

ID=80623476

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380024479.XA Pending CN118715010A (zh) 2022-03-01 2023-03-01 包含二苯基二唑衍生物的药物组合物及其使用方法

Country Status (12)

Country Link
US (1) US20250161273A1 (https=)
EP (1) EP4486340A1 (https=)
JP (1) JP2025508912A (https=)
KR (1) KR20240155237A (https=)
CN (1) CN118715010A (https=)
AU (1) AU2023227368A1 (https=)
CA (1) CA3246018A1 (https=)
CL (1) CL2024002379A1 (https=)
IL (1) IL314952A (https=)
MX (1) MX2024009773A (https=)
PE (1) PE20250781A1 (https=)
WO (1) WO2023166045A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025068949A1 (en) 2023-09-26 2025-04-03 Teva Pharmaceutical Industries Ltd. Emrusolmin for use in treating multiple system atrophy
KR20250090047A (ko) * 2023-12-12 2025-06-19 가천대학교 산학협력단 긴 탄소사슬을 포함하는 리파펜틴, 암포테리신 b, 세틸피리디늄, 도미펜, 토코페르솔란을 유효성분으로 포함하는 시누클레인병증 치료용 약제학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2687513B1 (en) * 2008-06-09 2020-12-02 Ludwig-Maximilians-Universität München Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
KR102671166B1 (ko) * 2015-12-14 2024-05-31 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 3,5-디페닐-디아졸 화합물의 수용성 유도체

Also Published As

Publication number Publication date
US20250161273A1 (en) 2025-05-22
CL2024002379A1 (es) 2025-01-24
WO2023166045A1 (en) 2023-09-07
KR20240155237A (ko) 2024-10-28
EP4486340A1 (en) 2025-01-08
MX2024009773A (es) 2024-08-19
IL314952A (en) 2024-10-01
CA3246018A1 (en) 2023-09-07
AU2023227368A1 (en) 2024-07-18
JP2025508912A (ja) 2025-04-10
PE20250781A1 (es) 2025-03-14

Similar Documents

Publication Publication Date Title
US20220152058A1 (en) Methods and compositions for treating various disorders
JP2019214598A (ja) 天然の併用ホルモン補充療法剤及び治療
JP2018162321A (ja) Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
JP2017081930A (ja) ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療
JP2017061482A (ja) ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
JP2018538273A (ja) 虚血性脳卒中を処置するための組成物および方法
AU2015264003A1 (en) Natural combination hormone replacement formulations and therapies
CN118715010A (zh) 包含二苯基二唑衍生物的药物组合物及其使用方法
JP2022502471A (ja) 化学療法誘発性の悪心および嘔吐を治療するための方法および製剤
WO2013059676A1 (en) Compositions for reduction of side effects
US20150174118A1 (en) Use of laquinimod to delay huntington's disease progression
HK40115748A (zh) 包含二苯基二唑衍生物的药物组合物及其使用方法
US20240165093A1 (en) Methods for treating familial chylomicronemia syndrome
EA052714B1 (ru) Фармацевтическая композиция, содержащая производные дифенилдиазола, и способ применения
JP2025534534A (ja) イソトレチノインを含む医薬組成物、その調製のためのプロセス及びその使用
KR20240004706A (ko) 신경내분비 종양을 치료하기 위한 조성물 및 방법
EP3700531B1 (en) Dosage regimen of paliperidone palmitate extended-release injectable suspension
EP4717262A1 (en) Pharmaceutical compositions of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
WO2025068949A1 (en) Emrusolmin for use in treating multiple system atrophy
WO2024210195A1 (ja) 炎症性腸疾患の治療用医薬組成物
WO2026083443A1 (en) Synergistic nutraceutical composition controlling osteoarthritis through inhibition of its nociceptive and neuropathic pain components
CN118742299A (zh) 监测患者对视网膜氧化性疾病治疗反应的方法
CN121466010A (zh) 阿托西班组合物及其用途
JP2023513669A (ja) テストステロン含有医薬組成物
IT201900013893A1 (it) Trattamento della steatosi epatica non alcolica

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40115748

Country of ref document: HK